Articles: function.
-
Pulmonary Function TestingSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: According to the predominant phenotype, patients suffering from Chronic Obstructive Pulmonary Oisease (COPO) may present varying and important nutritional profile alterations, up to extreme degrees of severe proteic-energetic malnutrition. In our study, Bioelectricallmpedance Analysis (BIA) has been used in the evaluation of nutritional status (with particular regards to body lean mass alterations) of patients suffering from COPDMETHODS: Up to now, 68 patients (46 M; mean age 70.6 yrs) affected by stable mild to very severe COPD (GOLD 2011 stages l-IV) were evaluated. All of them underwent body plethysmographic evaluation of pulmonary function, six-minute walking test (6MWT) and respiratory muscles strength evaluation (with maximum Inspiratory and expiratory pressures - MIP/MEP - assessment). Moreover, BIA variables were studied with Dietosystem Human Scan, that expresses either quantitative (BIA index) and qualitative (multifrequency relation and phase angle) body lean mass alterations. Furthermore, SIA data from a control age matched group were collected. ⋯ The following authors have nothing to disclose: Francesco De Blasio, Maria Grazia Santaniello, Francesca De Blasio, Giulia Miracco Berlingieri, Barbara Bellofiore, Luca ScalfiNo Product/Research Disclosure Information.
-
Comorbidities of OSA PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The cardiovascular complications(CVC) are the important causes of mortality/morbidity in OSAS. Hypoxia, vascular endothelial dysfunction and hypercoagulability are some of the pathophysiological mechanisms. In presence of hypoxia, hematocrit increases to maintain constant delivery of oxygen to the tissue. Hyperviscosity from increased hematocrit is one of the stimuli for atherosclerotic process. Mean platelet volume(MPV) is an indicator of platelet activation and was found to be an indicator for atherosclerosis. We investigated correlation between the hematocrit and MPV levels with the severity and response of OSAS to the CPAP therapy. ⋯ The following authors have nothing to disclose: Gülcan Çetin, Elif Kupeli, Serife Savas Bozbas, Füsun Öner EyüboğluNo Product/Research Disclosure Information.
-
Thoracic SurgerySESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Patients with non-small cell lung cancer (NSCLC) and synchronous brain metastases (BMs) on initial diagnosis, who presented with neurological deficits, had a short median survival and lower quality of life (QOL). We analyzed our experiences with surgical treatment of patients with NSCLC who had neurologically symptomatic, synchronous BMs. ⋯ The following authors have nothing to disclose: Minkwang Byun, Wou-Young ChungNo Product/Research Disclosure Information.
-
COPD Epidemiology & Physiology PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Purpose: Canada's fourth leading cause of death is chronic lower respiratory diseases including chronic obstructive pulmonary disease (COPD) and pneumonia. COPD is a leading cause of death worldwide and is frequently underdiagnosed and untreated. The objective of this paper is to determine the prevalence of airway obstruction (AO) and associated risk factors in farming and non-farming rural populations in Saskatchewan. ⋯ The following authors have nothing to disclose: Chandima Karunanayake, Josh Lawson, Donna Rennie, Louise Hagel, James Dosman, Punam PahwaNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe COPD experience marked deterioration in lung function and breathlessness compared to patients with mild-to-moderate COPD. We report improvement of dyspnea and lung function in patients with severe COPD in the BLAZE study with QVA149, a dual bronchodilator combining the long-acting β2-agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), versus placebo and tiotropium. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: Novartis, AstraZeneca, Forest Laboratories, Pfizer, Schering Plough, Grant monies (from industry related sources): GSK, Schering Plough, Methapharma, AstraZeneca, Merck Canada, Forest Laboratories, Novartis Donald Mahler: Grant monies (from industry related sources): Boehringer Ingelheim, Novartis, and Sunovion, Consultant fee, speaker bureau, advisory committee, etc.: GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion Tracy White: Employee: Novartis Pharmaceuticals Corporation Vijay Alagappan: Employee: Novartis Pharmaceuticals Corporation Hungta Chen: Employee: Novartis Pharmaceuticals Corporation Karoly Kulich: Employee: Novartis Pharma AG Nicola Gallagher: Employee: Novartis Horsham Research Centre Donald Banerji: Employee: Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Heinrich WorthClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.